GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lumos Pharma Inc (NAS:LUMO) » Definitions » Shiller PE Ratio

Lumos Pharma (Lumos Pharma) Shiller PE Ratio : (As of Jun. 01, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Lumos Pharma Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Lumos Pharma Shiller PE Ratio Historical Data

The historical data trend for Lumos Pharma's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lumos Pharma Shiller PE Ratio Chart

Lumos Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Lumos Pharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Lumos Pharma's Shiller PE Ratio

For the Biotechnology subindustry, Lumos Pharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lumos Pharma's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lumos Pharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Lumos Pharma's Shiller PE Ratio falls into.



Lumos Pharma Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Lumos Pharma's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Lumos Pharma's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-1.29/131.7762*131.7762
=-1.290

Current CPI (Mar. 2024) = 131.7762.

Lumos Pharma Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -2.970 100.560 -3.892
201409 -1.800 100.428 -2.362
201412 36.450 99.070 48.483
201503 3.150 99.621 4.167
201506 -4.410 100.684 -5.772
201509 -4.950 100.392 -6.497
201512 -6.750 99.792 -8.913
201603 -7.380 100.470 -9.680
201606 -10.080 101.688 -13.063
201609 -4.860 101.861 -6.287
201612 -4.140 101.863 -5.356
201703 -6.480 102.862 -8.301
201706 -5.130 103.349 -6.541
201709 -6.210 104.136 -7.858
201712 -3.330 104.011 -4.219
201803 -4.410 105.290 -5.519
201806 -4.230 106.317 -5.243
201809 -1.800 106.507 -2.227
201812 -2.520 105.998 -3.133
201903 -2.130 107.251 -2.617
201906 -2.470 108.070 -3.012
201909 -2.560 108.329 -3.114
201912 -1.980 108.420 -2.407
202003 -0.140 108.902 -0.169
202006 -0.650 108.767 -0.788
202009 0.210 109.815 0.252
202012 -0.310 109.897 -0.372
202103 -1.040 111.754 -1.226
202106 -0.990 114.631 -1.138
202109 -0.900 115.734 -1.025
202112 -0.680 117.630 -0.762
202203 -0.920 121.301 -0.999
202206 -1.860 125.017 -1.961
202209 -0.860 125.227 -0.905
202212 -0.980 125.222 -1.031
202303 -0.890 127.348 -0.921
202306 -1.980 128.729 -2.027
202309 -1.040 129.860 -1.055
202312 -1.170 129.419 -1.191
202403 -1.290 131.776 -1.290

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Lumos Pharma  (NAS:LUMO) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Lumos Pharma Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Lumos Pharma's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Lumos Pharma (Lumos Pharma) Business Description

Traded in Other Exchanges
N/A
Address
4200 Marathon Boulevard, Suite 200, Austin, TX, USA, 78756
Lumos Pharma Inc is a biopharmaceutical company that develops treatments for cancer and rare diseases. It carries out both clinical-stage and preclinical research on a range of molecules that help the immune system fight off cancer cells. The treatments are available orally and can be used in conjunction with other cancer therapies. The company also researches an Ebola vaccine. Lumos contracts with manufacturing organizations to make their treatments, engages in partnerships with pharmaceutical companies, and operates primarily in the United States.
Executives
David B Karpf officer: Chief Medical Officer 1360 WILLOW ROAD #100, MENLO PARK CA 94025
Aaron Schuchart officer: Chief Business Officer C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S.MOPAC EXPWY,BARTONOAKSPLAZONE,#250, AUSTIN TX 78746
Es-johansson An Van director 6863 BEE CAVE ROAD, SUITE 200, AUSTIN TX 78736
James E Flynn 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Joseph S Mccracken director C/O NEXVET BIOPHARMA PLC, NATL INST, FOSTERS AVENUE, MOUNT MERRION, BLACKROCK L2 00000
Richard J Hawkins director, officer: Chief Executive Officer 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404-2125
Emmett Cunningham director C/O RESTORATION ROBOTICS, INC., 128 BAYTECH DRIVE, SAN JOSE CA 95134
Kevin M. Lalande director 201 WEST 5TH STREET, AUSTIN TX 78701
John C. Mckew officer: Chief Scientific Officer C/O LUMOS PHARMA, 4200 MARATHON BLVD, STE 200, AUSTIN TX 78756
Deerfield Mgmt Iii, L.p. 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Private Design Fund Iii, L.p. 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Management Company, L.p. (series C) 10 percent owner, other: Possible Member of 10% Group 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Bradley J Powers officer: Principal Executive Officer C/O NEWLINK GENETICS CORPORATION, 2503 SOUTH LOOP DRIVE, AMES IA 50010
Lori D Lawley officer: Principal Accounting Officer C/O NEWLINK GENETICS CORPORATION, 2503 SOUTH LOOP DRIVE, AMES IA 50010
Ernest Iii Talarico director C/O NEWLINK GENETICS CORP., 2503 SOUTH LOOP DR., SUITE 5100, AIMES IA 50010